Ergo Bio Insights

Home
Archive
About
Life Sciences Careers: Issue #1
New jobs at Arrowhead Pharmaceuticals, 23andMe, Calico, etc.
Published on Life Sciences Careers • 
Investing in drug development is becoming more difficult
A third thought piece on the landscape of biotech venture
 • 
Vandon

September 2022

Meliora Therapeutics is building the full stack solution for MOA identification and polypharmacology
Molecular perturbations and phenotypic readouts for scalable MOA identification
 • 
Vandon
Founders of drug discovery engine companies need to kill four major risks
A second thought piece on the landscape of biotech venture
 • 
Vandon

May 2022

Reasons to be optimistic during this biotech recession
Conjectures on the recent developments in the biotech markets
 • 
Vandon

April 2022

Startups with platform technologies and infrastructure solutions
An investment thesis focused on composable and extensible innovations
 • 
Vandon
Community building in biotech venture
If innovation is the end product, people are the raw materials
 • 
Vandon

January 2022

A war between proponents of founder-led and VC-led venture models
An initial thought piece on the landscape of biotech venture
 • 
Vandon

March 2021

Trials: Stochastic simulations of clinical-stage therapeutic programs
Probability of success and costs associated with clinical trials
 • 
Vandon

February 2021

Advances: Protein degraders as a therapeutic modality
Molecular glues are promising pharmaceuticals for targeted protein degradation
 • 
Vandon
Deal: 23andMe to go public via SPAC sponsored by the Virgin Group
Genetic testing for consumers and biobank data for drug development
 • 
Vandon

January 2021

Year-in-review: 2020
COVID-19 pandemic and a surge in biotechnology funding
 • 
Vandon
© 2024 Ergo Bio
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture